The Helsinn Group and Eisai announced that the National Comprehensive Cancer Network (NCCN) has now included Akynzeo (netupitant/palonosetron) in the 2015 NCCN Antiemesis Guidelines as a recommended option for patients receiving both highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) is an evidence-based, consensus-driven document to assist in the decision-making process of individuals involved in cancer care, including physicians, nurses, pharmacists, payers, patients and their families. The Guidelines are also designed to help patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.

RELATED: Akynzeo Approved for Chemotherapy-Induced Nausea, Vomiting

Akynzeo is a substance P/neurokinin 1 (NK1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist indicated for the prevention of acute and delayed nausea and vomiting due to initial and repeat courses of chemotherapy, including highly emetogenic chemotherapy, in adults aged ≥18 years.

For more information visit